Kingdom Financial Group LLC. Sells 2,363 Shares of Johnson & Johnson $JNJ

Kingdom Financial Group LLC. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 75.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 770 shares of the company’s stock after selling 2,363 shares during the period. Kingdom Financial Group LLC.’s holdings in Johnson & Johnson were worth $159,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Van Hulzen Asset Management LLC grew its holdings in shares of Johnson & Johnson by 1.1% during the fourth quarter. Van Hulzen Asset Management LLC now owns 129,270 shares of the company’s stock worth $26,752,000 after purchasing an additional 1,378 shares during the last quarter. Goldenstone Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $1,247,000. FourThought Financial Partners LLC grew its holdings in shares of Johnson & Johnson by 0.7% during the fourth quarter. FourThought Financial Partners LLC now owns 15,404 shares of the company’s stock worth $3,188,000 after purchasing an additional 105 shares during the last quarter. Global Retirement Partners LLC grew its holdings in shares of Johnson & Johnson by 67.5% during the fourth quarter. Global Retirement Partners LLC now owns 58,519 shares of the company’s stock worth $12,111,000 after purchasing an additional 23,592 shares during the last quarter. Finally, KDT Advisors LLC grew its holdings in shares of Johnson & Johnson by 10.2% during the fourth quarter. KDT Advisors LLC now owns 5,395 shares of the company’s stock worth $1,116,000 after purchasing an additional 498 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received favorable coverage for its diversified pharma and MedTech businesses, with analysts saying its pipeline progress and stronger 2026 outlook make it better positioned than Pfizer despite patent risks. J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
• Positive Sentiment: The company announced China approval for nipocalimab, a regulatory win that expands the drug’s commercial potential and supports sentiment around J&J’s pipeline. Johnson & Johnson says nipocalimab approved in China
• Positive Sentiment: J&J also highlighted a next-generation coronary artery disease catheter, reinforcing growth prospects in its MedTech segment and ongoing innovation in interventional medicine. Johnson & Johnson (JNJ) Unveils Next-Gen Catheter for Coronary Artery Disease
• Positive Sentiment: J&J announced a collaboration to build a global intelligent operating room network with Abu Dhabi’s health department, adding another AI-driven MedTech initiative that could strengthen its long-term growth story. Johnson & Johnson Advances Creation of Global Intelligent OR Network
• Neutral Sentiment: J&J was included in broader dividend and blue-chip stock commentary, which may reinforce its reputation as a defensive income stock but does not appear to be a major direct driver. The Dividend Stocks That Can Replace a $65,000 Income and What They’ll Cost You
• Neutral Sentiment: Another article framed J&J as a defensive growth stock, supporting the bull case but offering little new fundamental information. Why Johnson & Johnson (JNJ) Still Fits a Defensive Growth Case
• Negative Sentiment: ImmunityBio said its ANKTIVA-based bladder cancer data shows a cost advantage versus J&J’s TAR-200, which could raise competitive pressure in an important oncology area. IBRX Says ANKTIVA Delivers Up To $314K Cost Advantage Over J&J’s TAR-200

Johnson & Johnson Trading Up 1.3%

NYSE:JNJ opened at $234.67 on Friday. Johnson & Johnson has a 1-year low of $149.04 and a 1-year high of $251.71. The business’s 50-day moving average price is $234.02 and its two-hundred day moving average price is $223.28. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $564.91 billion, a price-to-earnings ratio of 27.13, a PEG ratio of 2.27 and a beta of 0.27.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. During the same quarter in the prior year, the firm posted $2.77 earnings per share. The company’s quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities analysts expect that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be paid a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a yield of 2.3%. Johnson & Johnson’s payout ratio is currently 60.12%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Barclays increased their target price on Johnson & Johnson from $234.00 to $255.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 15th. Wells Fargo & Company upped their price target on Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a research note on Wednesday, April 15th. Argus upped their price target on Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a research note on Thursday, April 16th. Daiwa Securities Group upped their price target on Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a research note on Thursday, April 16th. Finally, Morgan Stanley set a $283.00 price target on Johnson & Johnson in a research note on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $253.04.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.